Tuberculosis Is Still Killing Over a Million People a Year — Here's Where and Why
TB kills roughly 3,700 people every day despite being curable since the 1940s. Here is who it kills, where, and why we still cannot stop it.
Somewhere in the world right now, a person is dying of tuberculosis. By the time you finish reading this sentence, another will have joined them. TB kills roughly one person every 23 seconds — and it has been doing this for as long as modern records have existed, through every decade that was supposed to be the one where we finally beat it.
You can watch the number climb in real time on our live death counter.
What makes this so difficult to accept is that tuberculosis is curable. It has been curable since 1944. The drugs exist. They are cheap. They work. And yet TB kills more people than any other single infectious agent on Earth — more than HIV, more than malaria, more than influenza. It has held that position for decades and shows no sign of giving it up.
The numbers
Tuberculosis kills approximately 1.35 million people every year. That figure comes from the WHO's latest Global Tuberculosis Report and includes only TB in HIV-negative people. When you add the roughly 167,000 TB deaths among people living with HIV, the total exceeds 1.5 million.
| Time period | TB deaths (HIV-negative) | Including HIV-positive |
|---|---|---|
| Per year | 1,350,000 | 1,517,000 |
| Per month | 112,500 | 126,417 |
| Per week | 25,962 | 29,173 |
| Per day | 3,699 | 4,156 |
| Per hour | 154 | 173 |
| Per minute | 2.6 | 2.9 |
That is 154 people dead from TB every hour, every day, every week of the year. In the time it takes to watch a football match, TB kills more people than were in the stadium.
For context, the global death toll from all causes is around 185,000 per day. TB accounts for roughly 2% of all deaths worldwide — from a single bacterium that we have known how to kill for 80 years.
A disease of poverty, not history
There is a common misconception in wealthy countries that tuberculosis is a historical disease — something Charles Dickens characters died of, not something that belongs in the 21st century. That misconception is one of the reasons TB remains so lethal.
TB is overwhelmingly a disease of poverty. Over 95% of TB deaths occur in low- and middle-income countries. The ten countries with the highest TB death rates account for nearly 75% of all cases globally.
| Country | Estimated TB deaths per year | Deaths per day | TB incidence rate (per 100,000) |
|---|---|---|---|
| India | 340,000 | 932 | 199 |
| Indonesia | 97,000 | 266 | 354 |
| China | 57,000 | 156 | 55 |
| Philippines | 48,000 | 132 | 638 |
| Pakistan | 43,000 | 118 | 264 |
| Nigeria | 82,000 | 225 | 219 |
| Bangladesh | 39,000 | 107 | 221 |
| DR Congo | 52,000 | 142 | 318 |
| Myanmar | 19,000 | 52 | 282 |
| Mozambique | 24,000 | 66 | 361 |
India alone accounts for roughly a quarter of all TB deaths worldwide. Nearly a thousand Indians die from TB every single day. That is more than the daily death toll from road accidents, suicide, and drowning in the country combined.
The Philippines has one of the highest incidence rates on this list — 638 cases per 100,000 people. That means roughly 1 in every 157 Filipinos develops active TB in any given year.
Why TB is so hard to stop
Tuberculosis is caused by Mycobacterium tuberculosis, a bacterium that spreads through the air when an infected person coughs, sneezes, or even speaks. It is not as contagious as measles, but it is far more patient. TB can live in the body for years — even decades — without causing symptoms. This dormant form is called latent TB, and an estimated 1.7 billion people worldwide are carrying it right now. That is roughly one in four humans.
Most of those 1.7 billion will never develop active disease. Their immune systems keep the bacteria in check indefinitely. But when the immune system weakens — through HIV, diabetes, malnutrition, ageing, or other stresses — latent TB can reactivate and become lethal.
This creates a massive, invisible reservoir of future cases that no amount of current treatment can empty.
| TB stage | People affected | Annual progression to active TB | Key risk factors |
|---|---|---|---|
| Latent TB (no symptoms) | 1.7 billion | 5–10% over a lifetime | HIV, diabetes, malnutrition, smoking |
| Active TB (infectious) | 10.6 million new cases/year | — | Same + overcrowding, poor ventilation |
| Drug-resistant TB (MDR/XDR) | 410,000 new cases/year | — | Incomplete treatment, poor drug supply |
| Deaths (all forms) | 1.5 million/year | — | Late diagnosis, lack of access to care |
The second reason TB persists is drug resistance. Standard TB treatment requires four drugs taken daily for six months. That is a long time. Many patients begin feeling better after a few weeks and stop taking the pills. Others cannot access the full course because of supply chain failures, cost, or distance from a clinic. Every incomplete course of treatment gives the bacteria a chance to evolve resistance.
Multi-drug resistant TB (MDR-TB) is resistant to the two most powerful first-line drugs — isoniazid and rifampicin. Treating MDR-TB takes 9 to 18 months, uses drugs with severe side effects (hearing loss, liver damage, psychosis), and costs 10 to 50 times more than standard treatment. Extensively drug-resistant TB (XDR-TB) is even harder to treat and has a mortality rate above 40%.
The HIV-TB collision
HIV and TB form the deadliest partnership in infectious disease. Each one accelerates the other.
A person living with HIV is 15 to 20 times more likely to develop active TB than someone without HIV. TB is the leading cause of death among people with HIV — not AIDS-defining cancers, not opportunistic infections, but tuberculosis. In sub-Saharan Africa, where both diseases are endemic, the overlap is devastating.
| Region | TB deaths in HIV-positive people (per year) | Share of all TB deaths |
|---|---|---|
| Sub-Saharan Africa | 110,000 | 66% of HIV-associated TB deaths |
| South-East Asia | 28,000 | 17% |
| Rest of world | 29,000 | 17% |
| Global total | 167,000 | 100% |
Two out of three HIV-associated TB deaths occur in sub-Saharan Africa. Countries like South Africa, Mozambique, Zimbabwe, and Lesotho have among the highest co-infection rates in the world. In Lesotho, roughly 72% of TB patients are also HIV-positive.
The tragedy is compounded by the fact that both diseases are treatable. Antiretroviral therapy controls HIV. Antibiotics cure TB. When both treatments are available and properly administered, most co-infected patients survive. When they are not — which is the case in precisely the places where co-infection is most common — people die of curable diseases in the thousands.
What TB treatment actually looks like
The standard treatment for drug-susceptible TB is called DOTS — Directly Observed Therapy, Short-course. It involves four antibiotics (isoniazid, rifampicin, pyrazinamide, and ethambutol) taken daily for two months, followed by isoniazid and rifampicin for four more months. When properly administered, it has a cure rate above 85%.
| Treatment type | Duration | Cost per patient | Cure rate | Side effects |
|---|---|---|---|---|
| Standard DOTS (drug-susceptible) | 6 months | £30–60 | 85–95% | Liver toxicity (rare), neuropathy |
| BPaL regimen (MDR-TB) | 6–9 months | £500–1,000 | 89% | Neuropathy, liver toxicity |
| Older MDR regimen | 18–20 months | £2,000–5,000 | 55–60% | Hearing loss, psychosis, liver damage |
| XDR-TB regimen | 18–24 months | £5,000–10,000+ | 40–60% | Severe, multiple organ effects |
The BPaL regimen (bedaquiline, pretomanid, and linezolid) represents the first significant advance in TB treatment in decades. Approved for drug-resistant TB, it shortened treatment from 18+ months to 6–9 months and dramatically improved cure rates. For the first time in years, drug-resistant TB became something close to manageable — if patients could access the drugs.
The problem, as with everything in TB, is access. The drugs exist. The regimens work. The barrier is getting them to the people who need them in the places where they need them.
The funding gap
TB is the world's deadliest infectious disease, but it is not funded like one. Annual global spending on TB research and development was roughly £1.7 billion in 2024 — less than half of what the WHO says is needed.
| Category | Annual spending (2024) | WHO target | Gap |
|---|---|---|---|
| TB prevention, diagnosis, treatment | £8.5 billion | £13 billion | £4.5 billion |
| TB research and development | £1.7 billion | £4 billion | £2.3 billion |
| Total | £10.2 billion | £17 billion | £6.8 billion |
Compare this to HIV, which receives roughly £16 billion annually in global funding despite killing fewer people than TB. Or compare it to COVID-19, which mobilised hundreds of billions within months. TB kills more people per year than COVID ever did — yet it receives a fraction of the attention and investment.
The reasons are grimly straightforward. TB kills poor people in poor countries. The people dying of TB have very little political or economic power. There is no wealthy constituency lobbying for TB funding the way there is for cancer or heart disease. The result is a disease that kills 1.5 million people a year and barely makes the news.
Children and TB
TB in children is a particularly neglected crisis within an already neglected crisis. An estimated 1.25 million children develop TB every year, and roughly 210,000 die from it — about 575 children every day.
| Age group | New TB cases per year | Deaths per year | Deaths per day |
|---|---|---|---|
| Under 5 | 650,000 | 120,000 | 329 |
| 5–14 | 600,000 | 90,000 | 247 |
| All children under 15 | 1,250,000 | 210,000 | 575 |
Children with TB are harder to diagnose because they often cannot produce the sputum samples needed for standard testing. They are harder to treat because child-friendly drug formulations were unavailable until recently. And they are more likely to die because their immune systems are less able to contain the infection.
For more on the broader picture of child mortality, see our analysis of how many children die every day.
The countries making progress
Not all the news is grim. Several countries have made significant progress in reducing TB deaths over the past two decades, proving that the disease can be beaten with sustained investment and political will.
| Country | TB deaths in 2005 | TB deaths in 2024 | Reduction |
|---|---|---|---|
| China | 170,000 | 57,000 | 66% |
| Ethiopia | 45,000 | 15,000 | 67% |
| Kenya | 32,000 | 11,000 | 66% |
| Tanzania | 25,000 | 9,000 | 64% |
| Russia | 30,000 | 7,000 | 77% |
Russia's 77% reduction is particularly notable given the country's severe MDR-TB problem. China's progress — cutting deaths by two thirds in under two decades — shows what is possible when a large country commits resources to TB control.
The common thread in all these success stories is the same: invest in diagnosis, fund treatment, and make sure patients complete their courses. None of this is revolutionary. None of it requires technology that does not already exist. It just requires money and sustained attention — the two things TB has always struggled to attract.
Why TB is not in your newsfeed
Tuberculosis kills more people than any other infectious disease. It has done so for at least two decades. And yet if you asked most people in the UK or the US to name the world's deadliest infection, they would guess HIV, malaria, or COVID — anything but TB.
The reasons:
It kills slowly. TB is not a dramatic, headline-grabbing disease. It does not sweep through populations in visible waves. It kills one person at a time, usually over weeks or months, in places with limited media presence.
It kills elsewhere. Over 95% of TB deaths occur in low- and middle-income countries. It barely registers in wealthy nations, which means it barely registers in the news cycles of wealthy nations.
It is old. TB has been killing humans for thousands of years. There is no novelty to it. COVID was new. Ebola was exotic. TB is the disease your great-great-grandparents died of, and that lack of novelty makes it almost invisible.
It kills the poorest. TB clusters in slums, prisons, refugee camps, and mining communities. The people most affected have the least power to demand attention, funding, or research.
The result is a disease that exists in a peculiar blind spot — too deadly to ignore in the data, too familiar and too far away to generate the political urgency that could actually end it.
What would it take to end TB
The WHO's End TB Strategy aims to reduce TB deaths by 95% by 2035 compared to 2015 levels. That would mean fewer than 70,000 TB deaths per year — down from 1.5 million. It is an ambitious target, and the world is nowhere near on track to meet it.
What would be needed:
| Intervention | Current status | What is needed |
|---|---|---|
| Diagnosis | 3.6 million cases undiagnosed/unreported per year | Universal access to rapid molecular testing (GeneXpert) |
| Treatment | 85% cure rate for drug-susceptible TB | 90%+ cure rate with shorter regimens for all forms |
| Prevention | 18% of eligible contacts receive preventive therapy | 90%+ coverage for household contacts and people with HIV |
| Vaccine | BCG (1921) — partially effective in children, unreliable in adults | New vaccine with 50%+ efficacy in adults |
| Funding | £10.2 billion/year | £17 billion/year |
The BCG vaccine — the only TB vaccine in existence — was developed in 1921. It provides some protection against severe forms of TB in children but is unreliable in adults. A new vaccine is the single intervention most likely to transform the epidemic, and several candidates are in advanced clinical trials. The M72/AS01E vaccine showed 50% efficacy in a Phase IIb trial — modest, but potentially game-changing at scale.
While you have been reading this
This article took roughly 11 minutes to read. In that time, approximately 41 people have died from tuberculosis. About 6 of them were children. Almost all of them lived in countries where a full course of TB treatment costs less than a round of drinks at a London pub.
The counter keeps running. You can see the full picture on our deaths today page, explore how TB compares to other leading causes, or check your own risk factors with our death clock tool.
Tuberculosis is not a mystery. We know what causes it. We know how to treat it. We know what it would cost to stop it. The bacterium has not outsmarted us — we have simply decided, collectively and repeatedly, that the people it kills are not worth the investment.
That is not a medical failure. It is a political one.
Data sources: WHO Global Tuberculosis Report 2024, The Lancet Infectious Diseases, Stop TB Partnership, Global Fund to Fight AIDS, Tuberculosis and Malaria, UNICEF. Figures are the most recent available estimates. This article is for informational purposes only.
You might also like
The 10 Countries With the Highest Death Rates (And What's Killing Their People)
Bulgaria, Chad, and the Central African Republic top very different lists. Here's why crude death rates and age-standardised death rates tell completely different stories — and what each reveals.
Dementia Deaths Have Doubled in 20 Years — What the Data Actually Shows
Dementia now kills 2.5 million people per year and has become the 7th leading cause of death worldwide. Here is what is driving the rise and what the numbers reveal.
The 5 Habits That Add the Most Years to Your Life (Backed by Data)
Adopting five simple habits can add 12-14 years to your life expectancy, according to a landmark Harvard study. Here is the data on what works, how much each habit matters, and why it is never too late to start.